A Bivalent Omicron-Containing Booster Vaccine against Covid-19

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · cited 1×

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection

Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,306

Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial

Gilbert, P. B., Montefiori, D. C., McDermott, A. B., Fong, Y., Benkeser, D., Deng, W., Zhou, H., Houchens, C. R., Martins, K., Jayashankar, L., et al. (2022) · Science · doi:10.1126/science.abm3425 · Cited by 1,137

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants

Pegu, A., O’Connell, S. E., Schmidt, S. D., O’Dell, S., Talana, C. A., Lai, L., Albert, J., Anderson, E., Bennett, H., Corbett, K. S., et al. (2021) · Science · doi:10.1126/science.abj4176 · Cited by 527

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination

Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O'Dell, S. J., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 447

Assembling the RNA therapeutics toolbox

Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 12

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission

Benlarbi, M., Ding, S., Bélanger, É., Tauzin, A., Poujol, R., Medjahed, H., Ferri, O. E., Bo, Y., Bourassa, C., Hussin, J., et al. (2024) · mBio · doi:10.1128/mbio.00907-24 · Cited by 12

Confounding and Negative Control Methods in Observational Study of SARS-CoV-2 Vaccine Effectiveness: A Nationwide, Population-Based Danish Health Registry Study

Obel, N., Fox, M. P., Tetens, M. M., Pedersen, L. H., Krause, T. G., Ullum, H., & Sørensen, H. T. (2024) · Clinical Epidemiology · doi:10.2147/clep.s468572 · Cited by 13

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults with Underlying Medical Conditions in the United States

Kopel, H., Nguyễn, V. H., Bogdanov, A., Winer, I. H., Boileau, C., Ducruet, T., Zeng, N., Winer-Jones, J. P., Esposito, D. B., Bausch-Jurken, M. T., et al. (2024) · Vaccines · doi:10.3390/vaccines12101107 · Cited by 12

Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults

Oyebanji, O. A., Mylonakis, E. E., & Canaday, D. H. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.11.002 · Cited by 13

COVID-19 vaccines and a perspective on Africa

Mantovani, A., Rescigno, M., Forni, G., Tognon, F., Putoto, G., Ictho, J., & Lochoro, P. (2023) · Trends in Immunology · doi:10.1016/j.it.2023.01.005 · Cited by 12

Bivalent second booster dose of the COVID-19 vaccine: Eligible populations’ reasons for receiving in Italy

Polla, G. D., del Giudice, G. M., Pelullo, C. P., & Angelillo, I. F. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2188856 · Cited by 12

The importance of equally accessible genomic surveillance in the age of pandemics

Zeghbib, S., Kemenesi, G., & Jakab, F. (2023) · Biologia Futura · doi:10.1007/s42977-023-00164-5 · Cited by 14

Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination

Cheng, S. M. S., Mok, C. K. P., Li, J. K. C., Chan, K. P., Luk, K. S., Lee, B. H. W., Gu, H., Chan, K., Tsang, L. C. H., Yiu, K. Y. S., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02335-9 · Cited by 12

Effectiveness of mRNA COVID-19 vaccine booster doses against Omicron severe outcomes

Grewal, R., Nguyen, L., Buchan, S. A., Wilson, S. E., Nasreen, S., Austin, P. C., Brown, K. A., Fell, D. B., Gubbay, J., Schwartz, K. L., et al. (2022) · doi:10.1101/2022.10.31.22281766 · Cited by 59

Early humoral and cellular responses after bivalent SARS‐CoV‐2 mRNA‐1273.214 vaccination in long‐term care and retirement home residents in Ontario, Canada: An observational cohort study

Breznik, J. A., Rahim, A., Bhakta, H., Clare, R., Zhang, A., Ang, J. C., Stacey, H. D., Liu, L., Kennedy, A. E., Bilaver, L., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29170 · Cited by 11

Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma

Aleman, A., van Kesteren, M., Zajdman, A. K., Srivastava, K., Cognigni, C., Mischka, J., Chen, L., Upadhyaya, B., Serebryakova, K., Nardulli, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104886 · Cited by 10

Oral delivery of a chitosan adjuvanted COVID-19 vaccine provides long-lasting and broad-spectrum protection against SARS-CoV-2 variants of concern in golden hamsters

Wang, S., Cui, H. Y., Zhang, C., Li, W., Wang, W., He, W., Feng, N., Zhao, Y., Wang, T., Tang, X., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105765 · Cited by 12

How much should we sequence? An analysis of the Swiss SARS-CoV-2 surveillance effort

Wegner, F., Gil, B. C., Araud, T., Beckmann, C., Beerenwinkel, N., Bertelli, C., Carrara, M., Cerutti, L., Chen, C., Cordey, S., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03628-23 · Cited by 11

Compressive pangenomics using mutation-annotated networks

Walia, S., Motwani, H., Tseng, Y.-H., Smith, K., Corbett-Detig, R. B., & Turakhia, Y. (2026) · Nature Genetics · doi:10.1038/s41588-025-02478-7 · Cited by 10

Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation

Lucca, F., Bezzerri, V., Danese, E., Olioso, D., Peserico, D., Boni, C., Cucchetto, G., Montagnana, M., Tridello, G., Meneghelli, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020908 · Cited by 11

Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2

Lee, K.-M., Lin, S., Wu, C.-J., & Kuo, R. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.01.002 · Cited by 14

Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing mono- and bivalent booster doses

Stecher, M., Kristoffersen, A. B., Lie, K., Andersen, S. R., Meijerink, H., & Starrfelt, J. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad114 · Cited by 11

Neutralizing antibody and CD8+ T cell responses following BA.4/5 bivalent COVID-19 booster vaccination in adults with and without prior exposure to SARS-CoV-2

Underwood, A. P., Sølund, C. S., Jacobsen, K., Binderup, A., Fernandez-Antunez, C., Mikkelsen, L. S., Inekci, D., Villadsen, S. L., Castruita, J. A. S., Pinholt, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1353353 · Cited by 11

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages

He, Q., Sun, S., Chen, X., Hu, Z., Zhang, Y., Peng, H., Fu, Y., Yang, J., & Chen, L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010146 · Cited by 11

An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19

Gupta, S. L., & Jaiswal, R. K. (2022) · Vaccines · doi:10.3390/vaccines11010079 · Cited by 11

Comparative Effectiveness of the Bivalent (Original/Omicron BA.4/BA.5) mRNA COVID-19 Vaccines mRNA-1273.222 and BNT162b2 Bivalent in Adults in the United StatesPreprint

Kopel, H., Nguyễn, V. H., Boileau, C., Bogdanov, A., Winer, I. H., Ducruet, T., Zeng, N., Bonafede, M., Esposito, D. B., Martin, D., et al. (2023) · medRxiv · doi:10.1101/2023.07.12.23292576 · Cited by 11

Persistent immune imprinting after XBB.1.5 COVID vaccination in humansPreprint

Tortorici, M. A., Addetia, A., Seo, A. J., Brown, J. T., Sprouse, K. R., Logue, J., Clark, E., Franko, N., Chu, H. Y., & Veesler, D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.28.569129 · Cited by 11

DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases

Zeng, Y. C., Young, O. J., Xiong, Q., Si, L., Ku, M., Bernier, S. G., Dembele, H., Isinelli, G., Gilboa, T., Swank, Z., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01614-w · Cited by 29

Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency

Milota, T., Smetanová, J., Skotnicová, A., Rataj, M., Lašťovička, J., Zelená, H., Paračková, Z., Fejtková, M., Kanderová, V., Froňková, E., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.10.046 · Cited by 10

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster

Wagenhäuser, I., Reusch, J., Gabel, A., Krone, L. B., Kurzai, O., Petri, N., & Krone, M. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.008 · Cited by 10

Structure-guided design of VAR2CSA-based immunogens and a cocktail strategy for a placental malaria vaccine

Ma, R., Salinas, N. D., Orr-Gonzalez, S., Richardson, B., Ouahes, T., Torano, H., Jenkins, B. J., Dickey, T. H., Neal, J., Duan, J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011879 · Cited by 10

Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study

Xu, S., Sy, L. S., Hong, V. X., Holmquist, K. J., Qian, L., Farrington, P., Bruxvoort, K. J., Klein, N. P., FIREMAN, B. H., Han, B., et al. (2024) · JMIR Public Health and Surveillance · doi:10.2196/53807 · Cited by 10

Unlocking insights: Navigating COVID-19 challenges and Emulating future pandemic Resilience strategies with strengthening natural immunity

Wimalawansa, S. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34691 · Cited by 11

Safety and Immunogenicity of an mRNA-1273 Booster in Children

Berthaud, V., Creech, C. B., Rostad, C. A., Carr, Q. O., de Leon, L., Dietrich, M., Gupta, A. K., Javita, D., Nachman, S., Pinninti, S. G., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae420 · Cited by 9

Improving the efficacy of cancer immunotherapy by host-defence caerin 1.1 and 1.9 peptides

Fu, Q., Luo, Y., Li, J., Zhang, P., Tang, S., Song, X., Fu, J., Liu, M., Mo, R., Wei, M. Q., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2385654 · Cited by 10

Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation

Sherman, A. C., Cheng, C., Swank, Z., Zhou, G., Li, X., Issa, N. C., Walt, D. R., Baden, L. R., & Soiffer, R. J. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.01.025 · Cited by 10

Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine

Qin, J., Jeon, J. H., Xu, J., Langston, L. K., Marasini, R., Mou, S., Montoya, B., Melo‐Silva, C. R., Jeon, H. J., Zhu, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1126392 · Cited by 11

SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants

Lindahl, H., Chen, P., Åberg, M., Ljunggren, H., Buggert, M., Aleman, S., Smith, C. I. E., & Bergman, P. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01486-8 · Cited by 10

Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or CoronaVac and heterologous boosting

Espíndola, O. D. M., Fuller, T. L., de Araújo, M. F., Tort, L. F. L., Guaraldo, L., Calvet, G. A., Resende, P. C., Bonaldo, M. C., Whitworth, J. A. G., Smith, C. E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-34035-9 · Cited by 10

T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets

Nowill, A. E., Caruso, M., & de Campos-Lima, P. O. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133225 · Cited by 10

Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models

Lelis, F., Byk, L. A., Pustylnikov, S., Nguyen, V., Nguyen, B. T., Nitz, M., Tarte, P., Tungare, K., Li, J., Manna, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46233-6 · Cited by 11

Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines

Lustig, Y., Barda, N., Weiss-Ottolenghi, Y., Indenbaum, V., Margalit, I., Asraf, K., Doolman, R., Chalkias, S., Das, R., Elfatarany, G., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.05.058 · Cited by 9

Trivalent SARS-CoV-2 S1 Subunit Protein Vaccination Induces Broad Humoral Responses in BALB/c Mice

Khan, M. S., Kim, E. S., Huang, S., Kenniston, T. W., & Gambotto, A. A. (2023) · Vaccines · doi:10.3390/vaccines11020314 · Cited by 11

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 9

Robust SARS-CoV-2 antibody and T cell immunity following three COVID-19 vaccine doses in inflammatory bowel disease patients receiving anti-TNF or alternative treatments

Zhang, E., Nguyen, T. H. O., Allen, L. F., Kedzierski, Ł., Rowntree, L. C., Chang, S. Y., Zhang, W., Habel, J. R., Foo, I. J. H., Menon, T., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-329136 · Cited by 10

Ending of the COVID-19 Related Public and National Health Emergency Declarations: Implications for Medically Underserved Populations in Tennessee

Alcendor, D. J., Matthews-Juarez, P., Smoot, D. T., Hildreth, J. E. K., & Juárez, P. D. (2024) · Archives of Internal Medicine Research · doi:10.26502/aimr.0164 · Cited by 9

Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study

Chen, C., Chen, C., Cao, L., Fang, J., & Xiao, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112022 · Cited by 10

Ancestral SARS-CoV-2 immune imprinting persists on RBD but not NTD after sequential Omicron infections

Wang, Z., Li, L., Du, R., Chen, X., Sun, Y., Qin, R., Li, Y., Feng, H., Hu, L., Chen, X., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111557 · Cited by 10

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious Diseases

Sokhangouy, S. K., Behzadi, M., Rezaei, S., Farjami, M., Haghshenas, M., Sefidbakht, Y., & Mozaffari‐Jovin, S. (2025) · Biotechnology Journal · doi:10.1002/biot.202400596 · Cited by 9

Systemic and Mucosal Antibody Responses to SARS-CoV-2 Variant-Specific Prime-and-Boost and Prime-and-Spike Vaccination: A Comparison of Intramuscular and Intranasal Bivalent Vaccine Administration in a Murine Model

Maltseva, M., Galipeau, Y., McCluskie, P. S., Castonguay, N., Cooper, C., & Langlois, M. (2025) · Vaccines · doi:10.3390/vaccines13040351 · Cited by 9

Neutralizing antibody durability and SARS-CoV-2 infection in older adults six months after XBB-containing vaccine booster

Chen, R.-R., Cao, G.-P., Song, X., Lu, M., Wang, M., Wang, X., Wang, M.-F., Wang, S.-Q., Wan, S., Yang, G., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02437-y · Cited by 11

mRNA therapeutics: Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access

Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115019 · Cited by 10

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol

Tan, N. H., Sablerolles, R. S. G., Rietdijk, W. J. R., Goorhuis, A., Postma, D. F., Visser, L. G., Bogers, S., Geers, D., Zaeck, L. M., Koopmans, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067749 · Cited by 9

SARS-CoV-2 infection-induced immunity reduces rates of reinfection and hospitalization caused by the Delta or Omicron variants

Vega, M.-A. D. L., Polychronopoulou, E., Ara, X. I. I. I., Ding, Z., Chen, T., Liu, Q., Lan, J., Nepveu-Traversy, M.-É., Fausther‐Bovendo, H., Zaidan, M., et al. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2169198 · Cited by 10

Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles

Borghi, M., Gallinaro, A., Pirillo, M. F., Canitano, A., Michelini, Z., Angelis, M. L. D., Cecchetti, S., Tinari, A., Falce, C., Mariotti, S., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147953 · Cited by 9

Lessons from SENCOVAC: A prospective study evaluating the response to SARS-CoV-2 vaccination in the CKD spectrum

Quiroga, B., Soler, M. J., Ortíz, A., & de Sequera, P. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.04.005 · Cited by 9

Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the treatment of SARS-CoV-2 infection in solid organ transplant recipients

Herrera, S., Aguado, J. M., Candel, F. J., Cordero, E., Domínguez‐Gil, B., Fernández‐Ruiz, M., Arcos, I. L., Len, Ó., Marcos, M. Á., Múñez, E., et al. (2023) · Transplantation Reviews · doi:10.1016/j.trre.2023.100788 · Cited by 9

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland

Ramasamy, M., Kelly, E. J., Seegobin, S., Dargan, P. I., Payne, R., Libri, V., Adam, M., Aley, P. K., Martinez-Alier, N., Church, A., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00177-5 · Cited by 9

A superior heterologous prime‐boost vaccination strategy against COVID‐19: A bivalent vaccine based on yeast‐derived RBD proteins followed by a heterologous vaccine

Liu, Y., Li, M., Cui, T., Chen, Z., Xu, L., Li, W., Peng, Q., Li, X., Zhao, D., Valencia, C. A., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29454 · Cited by 9

Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2

Braun, M. R., Martinez, C. I., Dora, E. G., Showalter, L. J., Mercedes, A. R., & Tucker, S. N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1086035 · Cited by 9

Humoral Responses Elicited by SARS-CoV-2 mRNA Vaccine in People Living with HIV

Marchitto, L., Chatterjee, D., Ding, S., Gendron‐Lepage, G., Tauzin, A., Boutin, M., Benlarbi, M., Medjahed, H., Sylla, M., Lanctôt, H., et al. (2023) · Viruses · doi:10.3390/v15102004 · Cited by 9

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

Zendt, M., Carrillo, F. A. B., Kelly, S., Saturday, T. A., DeGrange, M., Ginigeme, A., Wu, L., Callier, V., Ortega‐Villa, A. M., Faust, M. T., et al. (2023) · Science Advances · doi:10.1126/sciadv.adh3150 · Cited by 11

A deep generative model of the SARS-CoV-2 spike protein predicts future variantsPreprint

Dhodapkar, R. M. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.17.524472 · Cited by 9

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9

Monovalent XBB.1.5 booster vaccination induces a broad spectrum of SARS-CoV-2 neutralizing antibodies

Huo, N., Wu, S., Wang, Y., Wang, B., Zhang, Z., Zhang, J., Song, X., Hou, L., & Chen, W. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2286260 · Cited by 8

Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants

Gong, X., Peng, L., Wang, F., Liu, J., Tang, Y., Peng, Y., Niu, S., Yin, J., Guo, L., Lu, H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106208 · Cited by 8

Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine

Lee, W. S., Audsley, J., Trieu, M.-C., Reynaldi, A., Aurelia, L. C., Mehta, P. H., Patterson, J., Kent, H. E., Nguyen, J. T., Amarasena, T. H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181244 · Cited by 8

Estimates of vaccine effectiveness of the updated monovalent XBB.1.5 COVID-19 vaccine against symptomatic SARS-CoV-2 infection, hospitalization, and receipt of oxygen therapy in South Korea - October 26 to December 31, 2023

Lee, J. A., Jang, H., Ahn, S. M., Seong, J. E., Kim, Y. K., Sohn, Y., Jung, S., Jeong, H. W., Kim, S., Lee, J. S., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107249 · Cited by 8

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Klinkhardt, U., Schunk, M., Ervin, J. E., Schindler, C., Sugimoto, D. H., Rankin, B. M., Amann, R., Monti, M., Kutschenko, A., Schumacher, C., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2410574 · Cited by 8

Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection

Chen, J., Li, Y., & Liu, Z. (2023) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2023.101249 · Cited by 8

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5

Duan, M., Duan, H., An, Y., Zheng, T., Wan, S., Wang, H., Zhao, X., Dai, L., Xu, K., & Gao, G. F. (2023) · Emerging Microbes & Infections · doi:10.1080/22221751.2023.2179357 · Cited by 8

Saturation time of exposure interval for cross-neutralization response to SARS-CoV-2: Implications for vaccine dose interval

Miyamoto, S., Kuroda, Y., Kanno, T., Ueno, A., Shiwa-Sudo, N., Iwata‐Yoshikawa, N., Sakai, Y., Nagata, N., Arashiro, T., Ainai, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106694 · Cited by 6

Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core

Poumbourios, P., Langer, C., Boo, I., Zakir, T., Akerman, A., Milogiannakis, V., Aggarwal, A., Johnstone, B. A., Ha, J., Coulibaly, F., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1010981 · Cited by 8

Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response

Qiao, Y., Wotring, J. W., Zheng, Y., Zhang, C. J., Zhang, Y., Jiang, X., Pretto, C. D., Eyunni, S., Parolia, A., He, T., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221809120 · Cited by 8

Hybrid Immunity Provides the Best COVID-19 Humoral Response in Immunocompromised Patients with or without SARS-CoV-2 Infection History

Nazaruk, P., Tkaczyk, I., Monticolo, M., Jędrzejczak, A. M., Krata, N., Pączek, L., Foroncewicz, B., & Mucha, K. (2023) · Vaccines · doi:10.3390/vaccines11081380 · Cited by 8

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease

Yau, K., Kurtesi, A., Qi, F., Delgado-Brand, M., Tursun, T. R., Hu, Q., Dhruve, M. J., Kandel, C., Enilama, O., Levin, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41678-9 · Cited by 9

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study

Liu, Z., Alexander, J. L., Le, K., Zhou, X., Ibraheim, H., Anandabaskaran, S., Saifuddin, A., Lin, K. W., McFarlane, L. R., Constable, L. E., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102249 · Cited by 8

Humoral antibody response following mRNA vaccines against SARS-CoV-2 in solid organ transplant recipients; a status after a fifth and bivalent vaccine dose

Christophorou, E., Nilsson, A. C., Petersen, I., Lindvig, S. O., Davidsen, J. R., Abazi, R., Poulsen, M. K., Pedersen, R. M., Justesen, U. S., Johansen, N. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1270814 · Cited by 8

Review of pediatric emergency care and the COVID‐19 pandemic

Foster, A. A., Walls, T. A., Alade, K. H., Brown, K., Gausche‐Hill, M., Lin, S., Rose, E., Ruttan, T. K., Shahid, S., Sorrentino, A., et al. (2023) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.13073 · Cited by 7

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children

Priddy, F. H., Chalkias, S., Essink, B. J., Whatley, J. L., Brosz, A. B., Lee, I. T., Feng, J., Tracy, L. A., Deng, W., Zhou, W., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2397026 · Cited by 8

Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants

Shrestha, L. B., Tungatt, K., Aggarwal, A., Stubis, A., Fewings, N., Fichter, C., Akerman, A., Rodrigo, C., Tedla, N. T., Lee, S. C. L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105461 · Cited by 8

Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution

Li, L., Wei, Y., Han, Y., Yan, J., Li, X., Li, Z., Zhao, Y., Liang, H., & Wang, H. (2022) · Vaccines · doi:10.3390/vaccines10122035 · Cited by 8

Immune Responses against the Omicron Variant of SARS-CoV-2 after a Third Dose of COVID-19 Vaccine in Patients Living with Human Immunodeficiency Virus (PLWH): Comparison with Healthcare Workers

Park, J. H., Chung, H., Kim, M., Choi, S., & Chung, J.-W. (2022) · Vaccines · doi:10.3390/vaccines10122129 · Cited by 8

An Overview of Current Accomplishments and Gaps of COVID-19 Vaccine Platforms and Considerations for Next Generation Vaccines

Kale, A., Gaur, A., Menon, I., Chirmule, N. B., Bagwe, P., Jawa, R., Vijayanand, S., Patil, S., Suresh, S., & Jawa, V. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.01.019 · Cited by 8

Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations

Sudjaritruk, T., Mueangmo, O., Saheng, J., Winichakoon, P., Salee, P., Wongjak, W., Chaito, T., Praparattanapan, J., Nuket, K., Solai, N., et al. (2023) · Vaccines · doi:10.3390/vaccines11030564 · Cited by 8

COVID-19 vaccines based on viral nanoparticles displaying a conserved B-cell epitope show potent immunogenicity and a long-lasting antibody response

de Oliveira, J. F. A., Zhao, Z., Xiang, Y., Shin, M. D., Villaseñor, K. E., Deng, X., Shukla, S., Chen, S., & Steinmetz, N. F. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1117494 · Cited by 8

No Immunological Interference or Safety Concerns When Adjuvanted Recombinant Zoster Vaccine Is Coadministered With a Coronavirus Disease 2019 mRNA-1273 Booster Vaccine in Adults Aged 50 Years and Older: A Randomized Trial

Naficy, A., Kuxhausen, A., Pirrotta, P., Leav, B. A., Miller, J. M., Anteyi, K., Adams, M. S., Danier, J., Breuer, T., & Mwakingwe-Omari, A. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad361 · Cited by 10

Dilemmas and options for COVID-19 vaccination in children

Wen, J., Du, X., Li, A., Zhang, S., Shen, S., Zhang, Z., Yang, L., Sun, C., Li, J., & Zhu, S. (2023) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-023-01513-9 · Cited by 10

Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters

Abdelnabi, R., Pérez, P., Astorgano, D., Albericio, G., Kerstens, W., Thibaut, H. J., Coelmont, L., Weynand, B., Labiod, N., Delgado, R. B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1163159 · Cited by 8

Predictors of SARS-CoV-2 transmission in congregate living settings: a multicenter prospective study

Leis, J. A., Chan, C. K., Tan, C., Callahan, J., Serapion, V., Pascual, B., Lee, W., O’Brien, J., Thomas, N. R., Candon, H. L., et al. (2024) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2024.50 · Cited by 7

Computationally designed Spike antigens induce neutralising responses against the breadth of SARS-COV-2 variants

Vishwanath, S., Carnell, G., Billmeier, M., Ohlendorf, L., Neckermann, P., Asbach, B., George, C. L., Sans, M. S., Chan, A., Olivier, J., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00950-9 · Cited by 7

A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection

Liu, J., Wang, L., Kurtesi, A., Budylowski, P., Potts, K. G., Menon, H., Tan, Y., Samaan, P., Liu, X., Wang, Y., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01062-8 · Cited by 8

Evolving SARS-CoV-2 Vaccines: From Current Solutions to Broad-Spectrum Protection

Qiao, R., Li, J., Gong, J., Shao, Y., Yu, J., Chen, Y., Lu, Y., Yang, L., Lin, L., Hu, Z., et al. (2025) · Vaccines · doi:10.3390/vaccines13060635 · Cited by 8

Safety and Immunogenicity of aerosolized adenovirus-vectored COVID-19 vaccine and intramuscular mRNA vaccine bivalent boosters: a randomized open-label clinical trial

Wu, S., Huang, J., Wang, B., Li, J., Wu, J., Zhang, Z., Luo, L., Zhang, J., Huo, N., Long, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62698-7 · Cited by 8

A Potent Recombinant Polyclonal Antibody Therapeutic for Protection Against New Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern

Wayham, N. P., Niedecken, A. R., Simons, J. F., Chiang, Y., Medina‐Cucurella, A. V., Mizrahi, R. A., Wagner, E. K., Gras, A., Segal, I., Witte, P., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad102 · Cited by 7

Effectiveness of monovalent and bivalent COVID-19 vaccines

Silva, T. C., Boaventura, V. S., & Barral‐Netto, M. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00379-1 · Cited by 5

Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases

Liu, Y., Lu, J., Zhan, H., Yuan, W., Li, X., Kang, H., Li, H., Chen, Y., Cheng, L., Sun, X., et al. (2023) · Virologica Sinica · doi:10.1016/j.virs.2023.07.005 · Cited by 7

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

Esen, M., Fischer-Herr, J., Gabor, J. J., Gaile, M., Fleischmann, W. A., Smeenk, G. W., de Moraes, R. A., Bélard, S., Calle, C. L., Woldearegai, T. G., et al. (2024) · Vaccines · doi:10.3390/vaccines12111288 · Cited by 7

Advancing ORFV‐Based Therapeutics to the Clinical Stage

Helmold, M., & Amann, R. (2025) · Reviews in Medical Virology · doi:10.1002/rmv.70038 · Cited by 7

Associations of Immunogenicity and Reactogenicity After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine in the COVE and TeenCOVE Trials

Siangphoe, U., Baden, L. R., Sahly, H. M. E., Essink, B. J., Ali, K., Berman, G., Tomassini, J. E., Deng, W., Pajón, R., McPhee, R. A., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac780 · Cited by 7

COVID-19 in Patients with Hematologic Diseases

Casetti, I. C., Borsani, O., & Rumi, E. (2022) · Biomedicines · doi:10.3390/biomedicines10123069 · Cited by 8

A bias of Asparagine to Lysine mutations in SARS-CoV-2 outside the receptor binding domain affects protein flexibility

Boer, J. C., Pan, Q., Holien, J. K., Nguyen, T., Ascher, D. B., & Plebanski, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954435 · Cited by 7

Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir

Chen, P.-C., Huang, C.-C., Fu, C.-M., Chang, Y., Wu, P.-J., Lee, W., Lee, C., & Tsai, K. (2023) · Viruses · doi:10.3390/v15020543 · Cited by 7

Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers

Lee, D.-Y., Kang, D. Y., Kim, E., Lee, S.-J., Baek, J. H., Lee, J. S., Park, M. Y., & Im, J. H. (2023) · Medicine · doi:10.1097/md.0000000000033236 · Cited by 7

LB750. Safety and Immunogenicity of a Bivalent Omicron-Containing Booster Vaccine against COVID-19

Chalkias, S., Harper, C., Vrbicky, K. W., Walsh, S. R., Essink, B. J., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac492.1873

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Preprint

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2022) · medRxiv · doi:10.1101/2022.12.11.22283166 · Cited by 9

A Randomized Trial Comparing Omicron-Containing Boosters with the Original Covid-19 Vaccine mRNA-1273Preprint

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bethune, C., Nally, R., Bula, M., Kalra, P. A., Clark, R., Dargan, P. I., Boffito, M., et al. (2023) · medRxiv · doi:10.1101/2023.01.24.23284869 · Cited by 9

2363. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines: Interim Results From a Phase 3, Randomized, Observer-Blind, Active-Controlled Trial

Lee, I. T., Cosgrove, C. A., MOORE, P. J., Bula, M., Kalra, P. A., Dargan, P. I., Clark, R., Boffito, M., Sheridan, R., Bethune, C., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad500.1984 · Cited by 1

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results

Chalkias, S., Whatley, J. L., Eder, F. S., Essink, B. J., Khetan, S. K., Bradley, P., Brosz, A. B., McGhee, N., Tomassini, J. E., Chen, X., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02517-y · Cited by 72